STMN1 and hepatocellular carcinoma: Zhou et al. [33] found that down-regulated stathmin expression after STMN1 gene knockdown in hepatic carcinoma cell added 7.7-fold sensitivity to nab-paclitaxel and 2.7-fold sensitivity to solvent-based paclitaxel but no sensitivity to doxorubicin.